Pulmatrix, Inc. Common Stock
PULM
PULM: Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
moreShow PULM Financials
Recent trades of PULM by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by PULM's directors and management
Government lobbying spending instances
-
$16,000 Feb 03, 2011 Issue: Medical/Disease Research/Clinical Labs
-
$16,000 Oct 06, 2010 Issue: Medical/Disease Research/Clinical Labs
-
$16,000 Jul 15, 2010 Issue: Medical/Disease Research/Clinical Labs
-
$17,000 Apr 09, 2010 Issue: Medical/Disease Research/Clinical Labs
-
$16,000 Jan 20, 2010 Issue: Medical/Disease Research/Clinical Labs
-
$16,000 Nov 09, 2009 Issue: Medical/Disease Research/Clinical Labs
-
$16,000 Jul 13, 2009 Issue: Medical/Disease Research/Clinical Labs
-
$16,000 Apr 21, 2009 Issue: Medical/Disease Research/Clinical Labs
-
$20,000 Oct 20, 2008 Issue: Budget/Appropriations
-
$20,000 Jul 21, 2008 Issue: Budget/Appropriations
-
$20,000 Apr 21, 2008 Issue: Budget/Appropriations
New patents grants
-
Patent Title: Monovalent metal cation dry powders for inhalation May. 09, 2017
-
Patent Title: Cationic dry powders Sep. 06, 2016
-
Patent Title: Dry powder formulations and methods for treating pulmonary diseases Jan. 12, 2016
-
Patent Title: Dry powder formulations and methods for treating pulmonary diseases Jun. 23, 2015
-
Patent Title: Respirably dry powder comprising calcium lactate, sodium chloride and leucine Mar. 31, 2015
-
Patent Title: Respirably dry powder comprising calcium lactate, sodium chloride and leucine Jun. 24, 2014
-
Patent Title: Method and device for decreasing contamination Jan. 14, 2014
-
Patent Title: Formulations decreasing particle exhalation Nov. 26, 2013
-
Patent Title: Formulations decreasing particle exhalation May. 29, 2012
Federal grants, loans, and purchases
Followers on PULM's company Twitter account
Number of mentions of PULM in WallStreetBets Daily Discussion
Recent insights relating to PULM
Recent picks made for PULM stock on CNBC
ETFs with the largest estimated holdings in PULM
Flights by private jets registered to PULM